Welcome to Clozaril^® (clozapine) Connect

Clozaril^® Connect is a support programme to help diagnose, treat, and manage patients with
treatment resistant schizophrenia (TRS) who may benefit from clozapine
– the only treatment recommended by NICE for TRS.

>>Clozaril^® (clozapine) and COVID‐19 Information Update

HCP website

Clozaril^® Connect offers
a supportive HCP website to
provide in-depth and insightful
education on TRS.

This website is designed for
healthcare professionals only
– the content is not designed
for the general public.

Patient website

Clozaril^® Connect offers a patient/
carer information portal to provide
patients and carers with useful
insights into treatment resistance in
schizophrenia, and suggests simple
support plans on how to effectively
manage the side effects
of clozapine treatment.

This website is designed for healthcare
professionals, and patients (and carers of
patients) prescribed clozapine only – the
content is not designed for the general
public.

CPMS website

As part of the Clozaril^® Connect
support programme, Mylan
continues to offer the Clozaril^®
Patient Monitoring Service (CPMS)
for regular monitoring of Clozaril
patient WBC counts and ANC.

This website is designed for
healthcare professionals only
– the content is not designed
for the general public.


	SITE MAP \| TERMS & CONDITIONS \| PRIVACY POLICY

This website is owned and managed by Mylan. Copyright^® 2020 Mylan N.V. All rights reserved.
Mylan UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)
Clozaril^® is marketed by Mylan Products Limited in the UK, and Mylan IRE Healthcare Limited in Ireland. CLZ-2020-0023 Date of preparation: March 2020